99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study

99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry study

Bibliographic Details
Main Authors:	Lambert, Bieke, Carron, Philippe, D’Asseler, Yves, Bacher, Klaus, Van den Bosch, Filip, Elewaut, Dirk, Verbruggen, Gust, Beyaert, Rudi, Dumolyn, Caroline, De Vos, Filip
Format:	Online
Language:	English
Published:	Springer Berlin Heidelberg 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5151115/

Similar Items

Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis
by: Carron, Philippe, et al.
Published: (2016)

Active axial spondyloarthritis: potential role of certolizumab pegol
by: Ranatunga, Sriya, et al.
Published: (2014)

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
by: Rudwaleit, M., et al.
Published: (2016)

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis
by: Sieper, J., et al.
Published: (2015)

In-Vivo Biodistribution and Safety of 99mTc-LLP2A-HYNIC in Canine Non-Hodgkin Lymphoma
by: Zwingenberger, Allison L., et al.
Published: (2012)

Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
by: Henry, Alistair I, et al.
Published: (2011)

New biologics in the management of Crohn’s disease: focus on certolizumab pegol
by: Colombo, Elisabetta, et al.
Published: (2009)

Prefilled certolizumab pegol (Cimzia®) syringes for self-use in the treatment of rheumatoid arthritis
by: Rosa, J, et al.
Published: (2010)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn’s Disease
by: Blonski, Wojciech, et al.
Published: (2012)

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis
by: Furst, D E, et al.
Published: (2015)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
by: Sieper, J, et al.
Published: (2015)

Biodistribution of 99mTc Tricarbonyl Glycine Oligomers
by: Jang, Beom-Su, et al.
Published: (2012)

Biodistribution of 99mTc Labeled Integrin Antagonist
by: Jang, Beom-Su, et al.
Published: (2013)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
by: Hébuterne, Xavier, et al.
Published: (2013)

Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn’s Disease? A Meta-analysis of Controlled Clinical Trials
by: Nikfar, Shekoufeh, et al.
Published: (2013)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
by: Acosta-Felquer, María Laura, et al.
Published: (2016)

A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol
by: Curtis, Jeffrey R., et al.
Published: (2015)

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials
by: Combe, Bernard, et al.
Published: (2016)

Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis
by: Takeuchi, Tsutomu, et al.
Published: (2016)

Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity
by: Pope, Janet, et al.
Published: (2015)

Anti-TNF certolizumab pegol induces antioxidant response in human monocytes via reverse signaling
by: Boyer, Jean Frédéric, et al.
Published: (2016)

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure
by: Mease, P, et al.
Published: (2015)

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials
by: Bykerk, V P, et al.
Published: (2015)

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
by: Smolen, J S, et al.
Published: (2015)

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
by: Landewé, R, et al.
Published: (2014)

Radionuclide Imaging of Apoptosis in Malignancies: Promise and Pitfalls of 99mTc-Hynic-rh-Annexin V Imaging
by: Kartachova, M.S., et al.
Published: (2008)

99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies
by: Schaper, Frédéric L.W.V.J., et al.
Published: (2013)

The Diagnostic Efficiency of 99mTc-EDDA/HYNIC-Octreotate SPECT-CT in Comparison with 111In-Pentetrotide in the Detection of Neuroendocrine Tumours
by: Koçyiğit Deveci, Emel, et al.
Published: (2013)

A 99mTc-tricine-HYNIC-labeled Peptide Targeting the Melanocortin-1 Receptor for Melanoma Imaging
by: Shamshirian, Danial, et al.
Published: (2016)

Evaluation of 99mTc-HYNIC-βAla-Bombesin(7-14) as an agent for pancreas tumor detection in mice
by: Carlesso, F.N., et al.
Published: (2015)

99mTc-Labeled HYNIC-DAPI Causes Plasmid DNA Damage with High Efficiency
by: Kotzerke, Joerg, et al.
Published: (2014)

Reverse signalling of membrane TNF in human natural killer cells: a comparison of the effect of certolizumab pegol and other anti-TNF agents
by: Fossati, Gianluca, et al.
Published: (2011)

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
by: Strand, Vibeke, et al.
Published: (2011)

The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
by: Fleischmann, Roy
Published: (2009)

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
by: Koarada, Syuichi, et al.
Published: (2015)

Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain
by: Hidalgo-Vega, Álvaro, et al.
Published: (2015)

Simultaneous Exposure–Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol
by: Lacroix, B D, et al.
Published: (2014)

The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region
by: Mariette, X, et al.
Published: (2015)

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study
by: Gladman, D, et al.
Published: (2014)

Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study
by: Lee, Scott D., et al.
Published: (2016)